To date, the principal indications for liquid biopsy in CRC are: i) RAS and BRAF testing as substitute for tumor tissue analysis in stage IV metastatic CRC and ii) RAS mutational profiling for rechallenge in patients resistant to first line anti-EGFR therapies (27). This evidence concerns the gene BRAF and colorectal carcinoma.